lenvatinib,sunitinib,everolimus,pembrolizumab
merck,pfizer,eisai
['clear result', 'pembro', 'lenva']
clear results of frontline lenvatinib and pembro presented. high responses low primary pd. consistent messages from original nejm publication. favourable risk hr 0.94 but not stat sig #asco2023 
A medical oncologist that specializes in and focuses his research on urologic cancers.